This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Expanded access is no longer available for this treatment.
Information provided by:
Millennium Pharmaceuticals, Inc. Identifier:
First received: July 7, 2003
Last updated: February 13, 2007
Last verified: July 2003
The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE. The study is for patients who are not eligible for other clinical trials with VELCADE and for who VELCADE would otherwise not be available.

Condition Intervention
Multiple Myeloma Drug: Bortezomib

Study Type: Expanded Access     What is Expanded Access?
Official Title: An Open-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE in Patients With Relapsed Multiple Myeloma Who Have Failed Four or More Lines of Therapy

Resource links provided by NLM:

Further study details as provided by Millennium Pharmaceuticals, Inc.:

Estimated Enrollment: 1000

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Major Criteria:

  • Plasmacytomas on tissue biopsy
  • Bone marrow plasmacytosis (> 30% plasma cells)
  • Monoclonal IgG is > 3.5 g/dL or IgA is > 2.0 g/dL; kappa or lambda light chain excretion is > 1 g/day on a 24 hour urine sample.

Minor criteria:

  • Bone marrow plasmacytosis (10 to 30%)
  • Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria.
  • Lytic bone lesions

Other Eligibility Requirements:

  • Patient is not eligible for Millennium Study M34101-039.
  • Patient has received 4 or more lines of therapy for multiple myeloma and, in the investigator's opinion, currently needs therapy because of relapsed or progressive disease.
  • Patient is of legal consenting age, as defined by local regulations.
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  • Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
  • Female patients must be either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control throughout the study.
  • Male patients must agree to use an acceptable method of birth control throughout the study.
  • Patient has a Karnofsky performance status of greater than or equal to 60%.
  • Patient meets pretreatment laboratory criteria at and within 14 to 21 days before Baseline (Day 1 of Cycle 1, before study drug administration).

Exclusion Criteria:

  • Patient progressed while receiving VELCADE previously in a clinical trial.
  • Patient has been treated in Millennium Study M34101-039.
  • Patient received corticosteroids (> 10 mg/day prednisone or equivalent) within 1 week before enrollment in the study.
  • Patient received nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment in the study.
  • Patient received immunotherapy or antibody therapy within 4 weeks before enrollment.
  • Patient had major surgery with 4 weeks before enrollment (kyphoplasty isn't considered major surgery).
  • Patient has a history of allergic reactions due to compounds containing boron or mannitol.
  • Patient has peripheral neuropathy of Grade 2 or greater, as defined by the National Cancer Institute Common Toxicity Criteria (NCI CTC).
  • Patient has a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias or electrocardiogram shows evidence of acute ischemia or active conduction system abnormalities.
  • Patient has cardiac amyloidosis
  • Patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment.
  • Patient is known to be infected with human immunodeficiency virus (HIV positive).
  • Patient is known to be hepatitis B positive or has active hepatitis C infection.
  • Patient has an active systemic infection requiring treatment.
  • Female patient is pregnant or breast-feeding. Confirmation that the patient is not pregnant is required. Pregnancy testing is not required for post-menopausal or surgically sterilized patients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00063791

United States, Alabama
Michael Meshad, Oncology Center
Mobile, Alabama, United States, 36608
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Ohio
Toledo Clinic
Toledo, Ohio, United States, 43623
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
  More Information Identifier: NCT00063791     History of Changes
Other Study ID Numbers: M34102-052
Study First Received: July 7, 2003
Last Updated: February 13, 2007

Keywords provided by Millennium Pharmaceuticals, Inc.:
Relapsed or Refractory

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors processed this record on September 21, 2017